Intrathecal methotrexate

ApprovedSmall molecule

Amgen

Intrathecal methotrexate is one of 143 small molecule programs targeting Lymphoma. It is currently in Approved.

Indications

Total Trials

Active Trials

142

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Multiple SclerosisActive, not recruiting

Leptomeningeal MetastasisActive, not recruiting

MeningitisActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Multiple SclerosisPhase 1

Active, not recruiting

Leptomeningeal MetastasisPhase 2

Active, not recruiting

MeningitisApproved

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Intrathecal methotrexate

Amgen

Approved

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Oncaspar

SServier

Preclinical

15 5

Zofran

Novartis

Preclinical

2 6

Norvir

AbbVie

Preclinical

1 7

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 8

Tafasitamab

Incyte

Preclinical

7 9

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Kenalog

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia3 trials

Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00866749·120 enrolled

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed· Amgen logo

Amgen·Phase 1·NCT02303821·141 enrolled

Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL

Unknown status·SSun Yat-sen University·Phase 2·NCT02660762·100 enrolled

Multiple Sclerosis1 trial

Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 1·NCT02644044·30 enrolled

Central Nervous System1 trial

High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL

Unknown status·—·Phase 3·NCT03123718·205 enrolled

Meningitis1 trial

DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor

Completed· Pacira Pharmaceuticals, Inc logo

Pacira Pharmaceuticals, Inc·Phase 4·NCT00029523·100 enrolled

Leptomeningeal Metastasis1 trial

Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis

Completed·NNational Taiwan University Hospital·Phase 2·NCT01281696·40 enrolled

2 more indications

Relapsed or Refractory1 trial

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT01861002·15 enrolled

Lymphoma1 trial

Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

Completed·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT00210379·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Intrathecal methotrexate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intrathecal methotrexate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intrathecal methotrexate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Amgen

Intrathecal methotrexate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Lymphoblastic Leukemia3 trials

Multiple Sclerosis1 trial

Central Nervous System1 trial

Meningitis1 trial

Leptomeningeal Metastasis1 trial

Relapsed or Refractory1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News